Expression level is a key determinant of E2F1-mediated cell fate
- 17 February 2017
- journal article
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 24 (4) , 626-637
Abstract
The Rb/E2F network has a critical role in regulating cell cycle progression and cell fate decisions. It is dysfunctional in virtually all human cancers, because of genetic lesions that cause overexpression of activators, inactivation of repressors, or both. Paradoxically, the downstream target of this network, E2F1, is rarely strongly overexpressed in cancer. E2F1 can induce both proliferation and apoptosis but the factors governing these critical cell fate decisions remain unclear. Previous studies have focused on qualitative mechanisms such as differential cofactors, posttranslational modification or state of other signaling pathways as modifiers of the cell fate decisions downstream of E2F1 activation. In contrast, the importance of the expression levels of E2F1 itself in dictating the downstream phenotypes has not been rigorously studied, partly due to the limited resolution of traditional population-level measurements. Here, through single-cell quantitative analysis, we demonstrate that E2F1 expression levels have a critical role in determining the fate of individual cells. Low levels of exogenous E2F1 promote proliferation, moderate levels induce G1, G2 and mitotic cell cycle arrest, and very high levels promote apoptosis. These multiple anti-proliferative mechanisms result in a strong selection pressure leading to rapid elimination of E2F1-overexpressing cells from the population. RNA-sequencing and RT-PCR revealed that low levels of E2F1 are sufficient to induce numerous cell cycle-promoting genes, intermediate levels induce growth arrest genes (i.e., p18, p19 and p27), whereas higher levels are necessary to induce key apoptotic E2F1 targets APAF1, PUMA, HRK and BIM. Finally, treatment of a lung cancer cell line with a proteasome inhibitor, MLN2238, resulted in an E2F1-dependent mitotic arrest and apoptosis, confirming the role of endogenous E2F1 levels in these phenotypes. The strong anti-proliferative activity of moderately overexpressed E2F1 in multiple cancer types suggests that targeting E2F1 for upregulation may represent an attractive therapeutic strategy in cancer.Keywords
This publication has 38 references indexed in Scilit:
- DNA Damage Signals through Differentially Modified E2F1 Molecules To Induce ApoptosisMolecular and Cellular Biology, 2012
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer TherapyJNCI: Journal of the National Cancer Institute, 2012
- Viral-Mediated Noisy Gene Expression Reveals Biphasic E2f1 Response to MYCMolecular Cell, 2011
- Lysine Methylation Regulates E2F1-Induced Cell DeathMolecular Cell, 2010
- Regulation of E2F1-induced Apoptosis by the Nucleolar Protein RRP1BJournal of Biological Chemistry, 2010
- Division and apoptosis of E2f-deficient retinal progenitorsNature, 2009
- flowCore: a Bioconductor package for high throughput flow cytometryBMC Bioinformatics, 2009
- An E2F1-Dependent Gene Expression Program that Determines the Balance between Proliferation and Cell DeathCancer Cell, 2008
- TopBP1 recruits Brg1/Brm to repress E2F1-induced apoptosis, a novel pRb-independent and E2F1-specific control for cell survivalGenes & Development, 2004
- Cancer Cell CyclesScience, 1996